The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The lower effectiveness of PPARγ-targeting therapies in ApoE4 carriers may be due to impairment of PPARγ signaling mediated by ApoE4 through still unknown mechanisms.
“a lower effectiveness of PPARγ-targeting therapies has been observed in ApoE4 carriers and may be due to the impairment of PPARγ signaling mediated by ApoE4 through still unknown mechanisms [87].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [87]
A lower effectiveness of PPARγ-targeting therapies has been observed in ApoE4 carriers.
“a lower effectiveness of PPARγ-targeting therapies has been observed in ApoE4 carriers and may be due to the impairment of PPARγ signaling mediated by ApoE4 through still unknown mechanisms [87].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Jadad, A. R., Nichol, G., Penman, M., Tugwell, P., & Walsh, S. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00031-w · Cited by 1,308
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771
Insulin resistance and Alzheimer's disease
De La Monte, S. M. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.475 · Cited by 392
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355
Kobayashi, H., Ohnishi, T., Nakagawa, R., & Yoshizawa, K. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4405 · Cited by 79
Flagged first, then by citations
Research works printed but not linked: 19
- 8) Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimer’s Dis., 13, 323–331 (2008). · DOI
- 9) de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in alzheimer’s disease. Curr. Alzheimer Res., 9, 35–66 (2012). · DOI
- 10) Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics, 5, 481–489 (2008). · DOI
- 11) Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease. Ann. Pharmacother., 45, 1416–1424 (2011). · DOI
- 12) Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. PPAR gamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology, 153, 329–338 (2012). · DOI · Paper page
- 13) Zolezzi JM, Silva-Alvarez C, Ordenes D, Godoy JA, Carvajal FJ, Santos MJ, Inestrosa NC. Peroxisome proliferator-activated receptor (PPAR) gamma and PPAR alpha agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders? PLOS ONE, 8, e64019 (2013). · DOI
- 15) Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J. Am. Geriatr. Soc., 57, 177–179 (2009). · DOI
- 16) Hanyu H, Sato T, Sakurai H, Iwamoto T. The role of tumor necorsis factor-alpha in cognitive improvement after peroxime peroliferator-activator gamma agonist pioglitazone treatment in Alzeheimer’s disease. J. Am. Geriatr. Soc., 58, 1000–1001 (2010). · DOI
- 17) Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer’s disease. Neurobiol. Aging, 32, 1626–1633 (2011). · DOI · Paper page
- 21) Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer’s Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J., 6, 246–254 (2006). · DOI · Paper page
- 22) Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S. Rosiglitazone monotherapy in mild-tot-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord., 30, 131–146 (2010).
- 23) Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M. Rosiglitazone does not improve cogniton or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr. Alzheimer Res., 8, 592–606 (2011).
- 26) Higgins JP, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ, 343 (oct18 2), d5928 (2011). · DOI · Paper page
- 27) Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J. Clin. Epidemiol., 61, 991–996 (2008). · DOI · Paper page
- 28) Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer’s disease patients responding to treatment with rosiglitazone. Biomarkers, 13, 618–636 (2008). · DOI
- 29) To AW, Ribe EM, Chuang TT, Schroeder JE, Lovestone S. The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS ONE, 6, e16991 (2011). · DOI
- 30) Waring JF, Tang Q, Robieson WZ, King DP, Das U, Dubow J, Dutta S, Marek GJ, Gault LM. APOE-varepsilon4 carrier status and donepezil response in patients with Alzheimer’s disease. J. Alzheimer’s Dis., 47, 137–148 (2015). · DOI
- 31) Fukazawa R, Hanyu H, Sato T, Shimizu S, Koyama S, Kanetaka H, Sakurai H, Iwamoto T. Subgroups of Alzheimer’s disease associated with diabetes mellitus based on brain imaging. Dement. Geriatr. Cogn. Disord., 35, 280–290 (2013). · DOI
- 32) Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions, 5.0.2 ver. Wiley-Blackwell, Chichester (2008). · DOI · Paper page
Cited by
Sorted by citations
Staurenghi, E., Leoni, V., Lo Iacono, M., Sottero, B., Testa, G., Giannelli, S., Leonarduzzi, G., & Gamba, P. (2022) · Antioxidants · doi:10.3390/antiox11112168 · Cited by 24
Metadata
- Authors
- Iketani, R., Ohno, K., Kawasaki, Y., Matsumoto, K., Yamada, H., & Kishino, S.
- Affiliations
- Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University
- Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2018-07-01
- Volume
- 41
- Issue
- 7
- Pages
- 1017-1023
- ISSN
- 0918-6158
- 1347-5215
- Cited by
- 10
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
